Company: NDRA
Filing Date: 2025-11-06
Form Type: S-3
Source: 0001213900-25-107232
Chunk: 6

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-06
Form: S-3
Chunk 6
---
, policy and guidelines, including potential delays 
 in submitting required regulatory applications or other submissions with respect to U.S.  
 Food and Drug Administration (“FDA”) or other regulatory agency approval;                 |

| ● | our                                                                                              
 ability to obtain CE mark certification and secure required FDA and other governmental approvals 
 for our Thermo-Acoustic Enhanced Ultrasound (“TAEUS”) applications                               |

| ● | our                                                                                   
 ability to develop a commercially feasible application based on our TAEUS technology; |

| ● | market                        
 acceptance of our technology; |

| ● | the                                                 
 effect of macroeconomic conditions on our business; |

| ● | results                                                      
 of our human studies, which may be negative or inconclusive; |

| ● | our                                                
 ability to find and maintain development partners; |

| ● | our                                                                                       
 reliance on third parties, collaborations, strategic alliances and licensing arrangements 
 to complete our business strategy;                                                        |

| ● | the                                               
 amount and nature of competition in our industry; |

| ● | our                                           
 ability to protect our intellectual property; |

| ● | potential                                                                  
 changes in the healthcare industry or third-party reimbursement practices; |

| ● | our                                                                                         
 ability to comply with regulation by various federal, state, local and foreign governmental 
 agencies and to maintain necessary regulatory clearances or approvals;                      |

| ● | our                                                           
 ability to maintain compliance with Nasdaq listing standards; |

| ● | our                                                                                   
 ability to successfully adopt and execute on our new digital asset treasury strategy; |

| ● | risks                                                                                        
 related to regulatory developments regarding digital assets and digital asset markets, which 
 could adversely affect our business, financial condition, and results of operations;         |

| ● | the                                                              
 volatile and unpredictable cycles in the digital asset industry; |

| ● | any                                                    
 changes in the accounting treatment of digital assets; |

| ● | our                                           
 dependence on our senior management team; and |

| ● | the                                                                                         
 other risks and uncertainties described in the Risk Factors section of this prospectus, any 
 prospectus supplement and our most recent Annual Form 10-K and subsequently filed Quarterly 
 Reports on Form 10-Q, which filings are incorporated herein by reference.                   |

In some cases, you can identify
forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”,
“expects”, “plans”, “anticipates”, “believes”, “estimates”, “projects”,
“predicts”, “potential”